Huiyu Pharmaceutical (688553.SH): HY-2003 clinical trial application approved

Zhitong Finance App News, Huiyu Pharmaceutical (688553.SH) issued an announcement. The company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for HY-2003 independently developed by the company was approved.

It is reported that deoxycholic acid physically destroys adipocytes and triggers an inflammatory response, thereby encouraging macrophages to remove damaged fat cells and achieve the effect of dissolving localized fat. HY-2003 is a new dosage form containing deoxycholic acid to reduce adverse reactions at the injection site, shorten the interval between doses, speed up the effective time, and reduce the administration cycle. It is intended to improve moderate to severe prominent contours caused by fat accumulation under the chin in adults.